Oral phosphodiesterase type 5 inhibitors and priapism: A VigiBase analysis
Pharmacoepidemiology and Drug Safety · 2024
DOI: 10.1002/pds.5721 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2024. Verfasst von Behzad Abbasi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University of California San Francisco, San Francisco, California, USA. Hauptthemen laut MEDLINE: Priapism, Erectile Dysfunction, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
Purpose
To explore the differences of priapism events among a diverse cohort taking erectogenic medicines (i.e., phosphodiesterase type 5 inhibitors [PDE5i] and intracavernousal drugs). Method s We queried the World Health Organization global database of individual case safety reports (VigiBase) for records of the adverse drug reactions (ADR) with sildenafil, tadalafil, avanafil, vardenafil, papaverine, and alprostadil. Disproportionality analyses (case/non‐case approach) were performed to assess the reporting odds ratio (ROR) of priapism reporting in PDE5i consumers compared to intracavernousal drug recipients.
Results
From a total of 133 819 ADR events for erectogenic medications, 632 were priapism (PDE5is: n = 550, 0.41%; intracavernousal drugs: n = 82, 9.92%). Priapism disproportionality signals from intracavernousal drugs were 25 times stronger than PDE5is (ROR = 34.7; confidence interval [CI] 95%: 27.12–43.94 vs. ROR = 1.38; 95% CI: 1.24–1.54). For all PDE5i agents, the 12–17 years age group had the highest ROR (9.49, 95% CI: 3.76–19.93) followed by 2–11 years (4.31, 95% CI: 1.57–9.4). Disproportionality signals for consumers under 18 for both all PDE5is as a whole (ROR = 4.57, 95% CI: 2.48–7.73) and sildenafil (ROR = 4.89, 95% CI: 2.51–8.62) were stronger than individuals 18 or older (ROR = 1.06, 95% CI: 0.93–1.21 and ROR = 1.08, 95% CI: 0.91–1.26, respectively).
Conclusions
PDE5i use shows disproportionate priapism signals which are higher in young patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, University of California San Francisco, San Francisco, California, USA.
- Department of Urology, MedStar Georgetown University Hospital, Washington, District of Columbia, USA.
- Department of Plastic and Reconstructive Surgery, MedStar Georgetown University Hospital, Washington, District of Columbia, USA.
- Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA.
ORCID-Profile: Behzad Abbasi
Zitieren
APA
Abbasi, B., Shaw, N. M., Lui, J. L., Hakam, N., Nabavizadeh, B., & Breyer, B. N. (2024). Oral phosphodiesterase type 5 inhibitors and priapism: A VigiBase analysis. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.5721
Vancouver
Abbasi B, Shaw NM, Lui JL, Hakam N, Nabavizadeh B, Breyer BN. Oral phosphodiesterase type 5 inhibitors and priapism: A VigiBase analysis. Pharmacoepidemiology and Drug Safety. 2024. doi:10.1002/pds.5721
BibTeX
@article{Abbasi2024,
author = {Abbasi, Behzad and Shaw, Nathan M and Lui, Jason L and Hakam, Nizar and Nabavizadeh, Behnam and Breyer, Benjamin N},
title = {Oral phosphodiesterase type 5 inhibitors and priapism: A VigiBase analysis},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2024},
doi = {10.1002/pds.5721}
}
EUVIMED